Search Results 2401-2410 of 13403 for monoclonal antibody
... antibody) * Olaparib (a type of PARP inhibitor). Tissue Reinforcement For Breast Reconstruction (TRBR) Pivotal Clinical Study (REDEFINE). Jacksonville, Fla ...
Prior exposure to selected immune cell-modulating antibody regimens. Participating Mayo Clinic locations. Study statuses change often. Please contact the ...
... antibodies. Participating Mayo Clinic locations. Study statuses change often. Please contact the study team for the most up-to-date information regarding ...
Trastuzumab deruxtecan or another antibody-drug conjugate (ADC) consisting of an exatecan derivative. Have received treatment with: Any systemic anti-cancer ...
ROCHESTER, Minn. — A new Mayo Clinic study published in the New England Journal of Medicine has uncovered that an off-the-shelf, dual-antibody therapy can ...
Mayo Clinic's Immunometabolism and Cancer Immunology Lab led by Marion R. Curtis, Ph.D., focuses on immunotherapy and tumor antigens in ovarian cancer.
D. Internist; Oncologist; Hematologist. Rochester, MN. Areas of focus: CAR-T cell therapy, Bispecific antibody therapy, B-cell lymphoma, Non-Hodgkin lymphoma ...
... antibodies to the virus, and essentially had no remaining treatment options. Oncolytic virotherapy – using re-engineered viruses to fight cancer – has a ...
This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.